Conv. Plasma
Nigella Sativa

All remdesivir studies
Meta analysis
study COVID-19 treatment researchRemdesivirRemdesivir (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Mortality 49% Improvement Relative Risk SpO2<95% 58% Clinical improvement 56% Remdesivir for COVID-19  SARSTer  LATE TREATMENT Is late treatment with remdesivir beneficial for COVID-19? Retrospective 333 patients in Poland (March - August 2020) Greater improvement with remdesivir (p=0.01) Flisiak et al., Polish Archives of Int.., Nov 2020 Favors remdesivir Favors control

Remdesivir-based therapy improved recovery of patients with COVID-19 in the SARSTer multicentre, real-world study

Flisiak et al., Polish Archives of Internal Medicine, doi:10.20452/pamw.15735, SARSTer
Nov 2020  
  Source   PDF   All   Meta
Retrospective study comparing 122 remdesivir patients and 211 lopinavir/ritonavir patients, showing higher rates of clinical improvement with remdesivir and lower mortality (not statistically significant).
Gérard, Wu, Zhou show significantly increased risk of acute kidney injury with remdesivir.
risk of death, 48.9% lower, RR 0.51, p = 0.18, treatment 5 of 122 (4.1%), control 17 of 211 (8.1%), NNT 25, odds ratio converted to relative risk, all patients, day 28.
SpO2<95%, 58.0% lower, RR 0.42, p = 0.13, treatment 4 of 82 (4.9%), control 14 of 119 (11.8%), NNT 15, odds ratio converted to relative risk.
no clinical improvement, 56.5% lower, RR 0.44, p = 0.01, treatment 9 of 122 (7.4%), control 36 of 211 (17.1%), NNT 10, odds ratio converted to relative risk.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Flisiak et al., 3 Nov 2020, retrospective, Poland, peer-reviewed, 23 authors, study period 1 March, 2020 - 31 August, 2020, SARSTer trial. Contact:
This PaperRemdesivirAll
Remdesivir-based therapy improved recovery of patients with COVID-19 in the SARSTer multicentre, real-world study
Robert Flisiak, Dorota Zarębska-Michaluk, Aleksandra Berkan-Kawińska, Magdalena Tudrujek-Zdunek, Magdalena Rogalska, Anna Piekarska, Dorota Kozielewicz, Krzysztof Kłos, Marta Rorat, Beata Bolewska, Anna Szymanek-Pasternak, Włodzimierz Mazur, Beata Lorenc, Regina Podlasin, Katarzyna Sikorska, Barbara Oczko-Grzesik, Cezary Iwaszkiewicz, Bartosz Szetela, Paweł Pabjan, Małgorzata Pawłowska, Krzysztof Tomasiewicz, Joanna Polańska, Jerzy Jaroszewicz
Polish Archives of Internal Medicine, doi:10.20452/pamw.15735
Remdesivir use in COVID-19 103 supportive care was available, but the rapid worldwide spread of COVID-19 has raised a desperate need to invent an antiviral agent active against SARS-CoV-2. At first, the search for an effective therapy focused on drug repurposing and new ways of using approved agents with confirmed activity against other viruses. Among them, a compound of lopinavir and ritonavir was identified. Lopinavir, acting as an inhibitor of human immunodeficiency virus (HIV) protease, coadministered with ritonavir to increase its bioavailability, was demonstrated to have in vitro activity against both SARS-CoVs and MERS-CoVs. 1-5 The positive impact of lopinavir / ritonavir on the clinical outcome and reduction of the viral load in nasopharyngeal swabs was documented in patients participating in an open-label study performed during the outbreak of SARS in 2003. 2,3 Three case reports and a single retrospective study focused Introduction In December 2019, a new pathogen associated with an outbreak of respiratory tract infections was discovered in Wuhan, China. It was identified as a novel coronavirus termed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), closely related to the already known betacoronaviruses responsible for epidemics named with the acronyms SARS (severe acute respiratory syndrome) and MERS (Middle East respiratory syndrome). The outbreak of the disease cause by SARS-CoV-2, coronavirus disease 2019 (COVID-19), was announced a global pandemic by the World Health Organization (WHO) in March 2020. The clinical spectrum of SARS-CoV-2 infection ranges from asymptomatic or mild, selflimited respiratory tract disease to severe progressive pneumonia leading to acute respiratory distress syndrome and death due to multiorgan failure. At the beginning of the epidemic, only
Beigel, Tomashek, Dodd, Remdesivir for the treatment of Covid-19 -preliminary report, N Engl J Med, doi:10.1056/NEJMc2022236
Cai, Yang, Liu, Experimental treatment with favipiravir for COVID-19: an open-label control study, Engineering, doi:10.1016/j.eng.2020.03.007
Cao, Wang, Wen, A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19, N Engl J Med, doi:10.1056/NEJMc2008043
Chan, Yao, Yeung, Treatment with lopinavir/ritonavir or interferon-β1b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset, J Infect Dis, doi:10.1093/infdis/jiv392
Chen, Chan, Jiang, In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds, J Clin Virol, doi:10.1016/j.jcv.2004.03.003
Chu, Cheng, Hung, Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture, Antimicrob Agents Chemother, doi:10.1128/AAC.03011-14
Drożdżal, Rosik, Lechowicz, FDA approved drugs with pharmacotherapeutic potential for SARS-CoV-2 (COVID-19) therapy, Drug Resist Updat, doi:10.1016/j.drup.2020.100719
Flisiak, Horban, Jaroszewicz, Management of SARS -CoV -2 infection: recommendations of the Polish Association of Epidemiologists and Infectiologists. Annex no. 1 as of June 8, 2020, Pol Arch Intern Med, doi:10.20452/pamw.15658
Flisiak, Horban, Jaroszewicz, Management of SARS-CoV-2 infection: recommendations of the Polish Association of Epidemiologists and Infectiologists as of March 31, 2020, Pol Arch Intern Med, doi:10.20452/pamw.15424
Goldman, Lye, Hui, Remdesivir for severe COVID-19 versus a cohort receiving standard of care, Clin Infect Dis, doi:10.1056/NEJMoa2015301
Grein, Ohmagari, Shin, Compassionate use of remdesivir for patients with severe Covid-19, N Engl J Med
Infection ; Gilead, Merck, Roche, Berkan-Kawińska, particularly in patients with oxygen saturation ≤95%. ARTICLE InFORmATIOn ACknOwLEDgmEnTS The study was supported by the Polish Association of Epidemiologists and Infectiologists and Medical Research Agency
Kalil, Patterson, Mehta, Baricitinib plus remdesivir for hospitalized adults with Covid-19, N Engl J Med
Kim, Kim, Kwon, Lopinavir-ritonavir versus hydroxychloroquine for viral clearance and clinical improvement in patients with mild to moderate coronavirus disease 2019, Korean J Intern Med, doi:10.3904/kjim.2020.224
Kim, Won, Kee, Combination therapy with lopinavir/ritonavir, ribavirin and interferon-α for the Middle East respiratory syndrome, Antivir Ther, doi:10.3851/IMP3002
Lamb, Remdesivir: first approval, doi:10.1007/s40265-020-01378-w
Lecronier, Beurton, Burrel, Comparison of hydroxychloroquine, lopinavir/ritonavir, and standard of care in critically ill patients with SARS-CoV-2 pneumonia: an opportunistic retrospective analysis, Crit Care, doi:10.1186/s13054-020-03117-9
Mulangu, Dodd, Rt, A randomized, controlled trial of Ebola virus disease therapeutics, N Engl J Med, doi:10.1056/NEJMoa1910993
Pan, Peto, Henao-Restrepo, Repurposed antiviral drugs for Covid-19 -interim WHO Solidarity trial results, N Engl J Med
Rivera, Peters, Panagiotou, Utilization of COVID-19 treatments and clinical outcomes among patients with cancer: a COVID-19 and Cancer Consortium (CCC19) cohort study, Cancer Discov, doi:10.1158/2159-8290.CD-20-0941
Sheahan, Sims, Graham, Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses, Sci Transl Med, doi:10.1126/scitranslmed.aal3653
Spanakis, Tsiodras, Haagmans, Virological and serological analysis of a recent Middle East respiratory syndrome coronavirus infection case on a triple combination antiviral regimen, Int J Antimicrob Agents, doi:10.1016/j.ijantimicag.2014.07.026
Spinner, Gottlieb, Criner, Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial, JAMA
Tomasiewicz, Piekarska, Stempkowska-Rejek, Tocilizumab for patients with severe COVID-19: a retrospective, multi-center study, Expert Rev Anti Infect Ther, doi:10.1080/14787210.2020.1800453
Wang, Cao, Zhang, Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro, Cell Res, doi:10.1038/s41422-020-0282-0
Yamamoto, Yang, Yoshinaka, HIV protease inhibitor nelfinavir inhibits replication of SARS-associated coronavirus, Biochem Biophys Res Commun, doi:10.1016/j.bbrc.2004.04.083
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop